$9.72
+0.10%Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Chief Accounting Officer
Compensation
$536,789
Chief Compliance & Risk Officer
Chief Financial Officer
Compensation
$1,127,586
Chief Human Resources Officer
Chief Investor Relations & Communications Officer
Chief Legal Officer & Corporate Secretary
Compensation
$794,279
Chief People & Business Operations Officer
Compensation
$875,768
President of Global Operations & Quality
President of the Global Spine Business
Compensation
$1,193,443
President, Chief Executive Officer & Director
Compensation
$2,072,810
During the last 12 months, insiders have purchased $4.43M and sold $917K worth of OFIX shares, resulting in $3.51M of net buying activity.
258.5K
2.79M
8.0K
98.87K
+2.7M
+$2.69M
127.0K
1.60M
52.6K
731.74K
+866K
+$866K
0
0.00
0
0.00
+0
+$0
3.5K
38.45K
7.4K
86.67K
-48K
-$48K
Juniper Investment Company, Llc
10 Percent Owner
$2.59M
Engine Capital Management, Lp
10 Percent Owner
$1.72M
Henneman John B Iii
Director
$61K
Capps Vickie L
Director
$30K
Bazaar Alan Lee
Director
$25K
Calafiore Massimo
Director, Officer: President & Ceo
$457K
Andrews Julie
Officer: Cfo
$131K
Cedron Jorge Andres
Officer: Clo
$83K
Vitale Lucas
Officer: Cp&Boo
$80K
Mcpherron Aviva
Officer: Pres, Global Ops & Qual
$72K
Strong bullish signal with $3.51M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
OFIX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | June 18, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | April 29, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 27, 2023 | April 27, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 06, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 21, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 08, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 29, 2019 | June 10, 2019 | 2019 | |
DEF 14A DEF 14A 2017 N/A | April 28, 2017 | June 13, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | April 29, 2016 | June 14, 2016 | 2016 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.